Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis

Scandinavian Journal of Immunology

Volumn 68, Issue 1, 2008, Pages 103-111

  Andersson, A K ^a   Feldmann, M ^a   Brennan, F M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 6; MESSENGER RNA; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL PROLIFERATION; CHIMERA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; NATURAL KILLER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-15; INTERLEUKINS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE;

EID: 44849114296     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02118.x     Document Type: Article

References (59)

1. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989 2 : 244 7.
2. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992 89 : 9784 8.
3. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995 6 : 225 30.
4. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 1991 21 : 2575 9.
5. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996 14 : 397 440.
6. Maini RN, Breedveld FC, Kalden JR et al. Randomized placebo-controlled trial of multiple intravenous infusions of anti-TNFα monoclonal antibody with or without weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 41 : 1552 63.
7. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000 343 : 1586 93.
8. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997 337 : 141 7.
9. Choy EH, Hazleman B, Smith M et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002 41 : 1133 7.
10. Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993 36 : 1681 90.
11. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 344 : 1105 10.
12. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007 56 : 1232 9.
13. De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life. J Dermatolog Treat 2006 17 : 355 8.
14. van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004 63 : 508 16.
15. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001 97 : 14 32.
16. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002 17 : 537 47.
17. Bulanova E, Budagian V, Duitman E et al. Soluble IL-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. J Biol Chem 2007 282 : 13167 79.
18. Budagian V, Bulanova E, Orinska Z et al. Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). J Biol Chem 2004 279 : 40368 75.
19. Thurkow EW, van der Heijden IM, Breedveld FC et al. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol 1997 181 : 444 50.
20. Ernestam S, af Klint E, Catrina AI et al. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor. Arthritis Res Ther 2006 8 : R18.
21. Harada S, Yamamura M, Okamoto H et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 1999 42 : 1508 16.
22. Oppenheimer-Marks N, Brezinschek RI, Mohamadzadeh M, Vita R, Lipsky PE. Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells in vitro and in the SCID mouse-human rheumatoid arthritis model in vivo. J Clin Invest 1998 101 : 1261 72.
23. McInnes IB, al-Mughales J, Field M et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996 2 : 175 82.
24. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997 3 : 189 95.
25. Kurowska M, Rudnicka W, Kontny E et al. Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. J Immunol 2002 169 : 1760 7.
26. Baslund B, Tvede N, Danneskiold-Samsoe B et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005 52 : 2686 92.
27. Parrish-Novak J, Dillon SR, Nelson A et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000 408 : 57 63.
28. Di Carlo E, Comes A, Orengo AM et al. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 2004 172 : 1540 7.
29. Wang G, Tschoi M, Spolski R et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003 63 : 9016 22.
30. Ma HL, Whitters MJ, Konz RF et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol 2003 171 : 608 15.
31. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004 117 : 265 77.
32. Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi FD. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 2005 174 : 2696 701.
33. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007 178 : 3822 30.
34. Young DA, Hegen M, Ma HL et al. Blockade of the interleukin-21/ interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007 56 : 1152 63.
35. Li J, Shen W, Kong K, Liu Z. Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. Scand J Immunol 2006 64 : 515 22.
36. Jungel A, Distler JH, Kurowska-Stolarska M et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004 50 : 1468 76.
37. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 31 : 315 24.
38. Brennan FM, Chantry D, Turner M, Foxwell B, Maini R, Feldmann M. Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures. Clin Exp Immunol 1990 81 : 278 85.
39. Rappl G, Kapsokefalou A, Heuser C et al. Dermal fibroblasts sustain proliferation of activated T cells via membrane-bound interleukin-15 upon long-term stimulation with tumor necrosis factor-alpha. J Invest Dermatol 2001 116 : 102 9.
40. Miranda-Carus ME, Balsa A, Benito-Miguel M, Perez de Ayala C, Martin-Mola E. IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. J Immunol 2004 173 : 1463 76.
41. Miranda-Carus ME, Benito-Miguel M, Balsa A et al. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 2006 54 : 1151 64.
42. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol 1998 160 : 5654 60.
43. Sebbag M, Parry SL, Brennan FM, Feldmann M. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol 1997 27 : 624 32.
44. Buchan G, Barrett K, Fujita T, Taniguchi T, Maini R, Feldmann M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin Exp Immunol 1988 71 : 295 301.
45. Lundy SK, Sarkar S, Tesmer LA, Fox DA. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther 2007 9 : 202.
46. Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology 2005 12 : 183 9.
47. Monteleone G, Monteleone I, Fina D et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005 128 : 687 94.
48. Fina D, Sarra M, Caruso R et al. Interleukin-21 contributes to the mucosal T helper cell type 1 response in celiac disease. Gut 2007 (in press).
49. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004 4 : 617 29.
50. Monteleone G, Caruso R, Fina D et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006 55 : 1774 80.
51. Martel-Pelletier J, Welsch DJ, Pelletier JP. Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 2001 15 : 805 29.
52. Evans HG, Suddason T, Jackson I, Taams LS, Lord GM. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci U S A 2007 104 : 17034 9.
53. Hoeve MA, Savage ND, de Boer T et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006 36 : 661 70.
54. Fantini MC, Rizzo A, Fina D et al. IL-21 regulates experimental colitis by modulating the balance between T(reg) and Th17 cells. Eur J Immunol 2007 37 : 3155 63.
55. Peluso I, Fantini MC, Fina D et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007 178 : 732 9.
56. Korn T, Bettelli E, Gao W et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007 448 : 484 7.
57. Nurieva R, Yang XO, Martinez G et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007 448 : 480 3.
58. Zhou L, Ivanov II, Spolski R et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007 8 : 967 74.
59. Habib T, Nelson A, Kaushansky K. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J Allergy Clin Immunol 2003 112 : 1033 45.